Gandhinagar (Gujarat), June 25 (ANI): Gujarat Biotechnology University (GBU), in collaboration with Celliimune Biotech, is spearheading a transformative initiative to develop a cost-effective, indigenous version of CAR-T cell therapy—an advanced cancer treatment currently priced at ₹3–4 crore per dose abroad. With support from the Gujarat government, GBU will focus on cutting-edge research, while Celliimune leads production and clinical trials. CAR-T therapy involves genetically modifying a patient’s T-cells to identify and destroy cancer cells, especially in leukemia and lymphoma cases, showing remarkable success even in terminal patients. This effort aims to make life-saving treatment accessible and affordable, placing India on the global map of cancer innovation
00:01At Gujarat Biotechnology University, a breakthrough is in motion.
00:07In partnership with Celli Immune Biotech, the university is developing an indigenous version of CAR T cell therapy,
00:15an advanced cancer treatment currently priced beyond reach at 3 to 4 crore rupees per dose abroad.
00:23Backed by progressive policies of the state government, the Gujarat Biotechnology University will focus on R&D while Celli Immune handles production and trials, aiming to slash costs and save lives.
00:40The CAR T therapy is such a therapy that is very expensive.
00:47If I talk about the U.S.A., the cost is around 4 to 5 lakh dollars per dose.
00:54It is one dose.
00:55But 4 to 5 lakh U.S. dollars, that's huge.
00:59It's as good as that the majority of the Indian population of the majority of the Indian population doesn't have a therapy.
01:06So, if we create it in India, we will create it from homegrown technologies, production, production, everything we will do.
01:14And we will rely less on the foreign suppliers.
01:19If we rely less on the foreign suppliers, the cost will automatically go down.
01:24And that's how we can make it affordable to our Indian population.
01:28If there are such things, which I have to be getting, 50-60 lakh rupees,
01:33it's not that it's not my income, where will it be?
01:38It's not that it's not that it's for many people.
01:40It's not that it's for many people.
01:42It's for our people.
01:43So, if we can reduce the cost to this project,
01:47which is the biggest thing for this project,
01:49then there will be a possibility of being able to save lives.
01:55In the meantime, this is blood cancer.
01:57But this is the basis that we call CAR-T cell.
02:00This is the basis that you have a blood cancer fluid,
02:03but you can also approach the tumor of cancer.
02:06CAR-T therapy modifies a patient's T cells to target and destroy cancer.
02:15Especially effective in leukemia and lymphoma,
02:19it has shown dramatic results, even in terminal cases.
02:23CAR-T therapy is a new era of precision medicine.
02:33In this therapy, what do we do?
02:35We take out the blood from the human patients,
